Weber J, Glutsch V, Geissinger E, et al. - Recent studies indicate that long-term tumor control was correlated with a pathological response achieved by neoadjuvant immunotherapy and that short neoadjuvant application of checkpoint inhibitors can be superior to adjuvant therapy. In this case reports, neoadjuvant immunotherapy was conducted in three individuals with lymph node and satellite or in transit metastases, and in one patient with an advanced primary and lymph node metastases. All patients in all metastatic sites and in the advanced primary obtained a radiological objective response and a pathological response (partial or complete). So far, none of the patients has relapsed.